MCID: CNV002
MIFTS: 42

Conversion Disorder

Categories: Rare diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Conversion Disorder

MalaCards integrated aliases for Conversion Disorder:

Name: Conversion Disorder 12 76 53 44 15 73
Hysterical Neurosis, Conversion Type 12
Functional Neurological Disorder 53
Conversion Hysteria or Reaction 12
Conversion Hysterical Neurosis 12
Functional Movement Disorder 53
Dissociative Disorder 73
Fnd 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1768
ICD10 33 F44
ICD9CM 35 300.11
MeSH 44 D003291
UMLS 73 C0009946

Summaries for Conversion Disorder

NIH Rare Diseases : 53 Conversion disorder is a disorder in which a person experiences blindness, paralysis, or other symptoms affecting the nervous system that cannot be explained solely by a physical illness or injury. Symptoms usually begin suddenly after a period of emotional or physical distress or psychological conflict. Conversion disorder is thought to be caused by the body’s reaction to a stressful physical or emotional event. Some research has identified potential neurological changes that may be related to symptoms of the disorder. Diagnosis of conversion disorder is based on identifying particular signs that are common among people with the disorder, as well as performing tests to rule out other causes of the symptoms. Treatment may include psychotherapy, hypnosis, and stress management training to help reduce symptoms. Treatment of any underlying psychological disorder is also recommended. The affected body part may require physical or occupational therapy until symptoms resolve.

MalaCards based summary : Conversion Disorder, also known as hysterical neurosis, conversion type, is related to frontonasal dysplasia 1 and psychogenic movement, and has symptoms including waxy flexibility An important gene associated with Conversion Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways is Biogenic Amine Synthesis. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain, and related phenotypes are endocrine/exocrine gland and respiratory system

Disease Ontology : 12 A somatoform disorder that involves numbness, blindness, paralysis or fits without a neurological cause.

Wikipedia : 76 Conversion disorder (CD) is a diagnostic category used in some psychiatric classification systems. It is... more...

Related Diseases for Conversion Disorder

Diseases related to Conversion Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 frontonasal dysplasia 1 11.9
2 psychogenic movement 11.2
3 six2-related frontonasal dysplasia 10.9
4 dissociative disorder 10.6
5 lymphoma 10.1
6 depression 9.9
7 dissociative amnesia 9.9
8 alexithymia 9.8
9 reflex sympathetic dystrophy 9.8
10 anorexia nervosa 9.8
11 anxiety 9.8
12 algoneurodystrophy 9.8
13 epilepsy 9.8
14 dissociative seizures 9.8
15 dysbaric osteonecrosis 9.7 ALX3 COMT
16 multiple sclerosis 9.7
17 aging 9.7
18 hemiplegia 9.7
19 disease of mental health 9.6 COMT GAD1
20 creutzfeldt-jakob disease 9.5
21 dementia, lewy body 9.5
22 systemic lupus erythematosus 9.5
23 neurodegeneration with brain iron accumulation 1 9.5
24 incontinentia pigmenti 9.5
25 paine syndrome 9.5
26 supranuclear palsy, progressive, 1 9.5
27 leukemia, acute myeloid 9.5
28 west nile virus 9.5
29 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.5
30 brain injury 9.5
31 leukemia 9.5
32 ptosis 9.5
33 thrombosis 9.5
34 sensorineural hearing loss 9.5
35 tetanus 9.5
36 epidural abscess 9.5
37 myopia 9.5
38 arachnoiditis 9.5
39 locked-in syndrome 9.5
40 guillain-barre syndrome 9.5
41 hypochondriasis 9.5
42 dementia 9.5
43 somatization disorder 9.5
44 impotence 9.5
45 astrocytoma 9.5
46 complex regional pain syndrome 9.5
47 cerebritis 9.5
48 multiple chemical sensitivity 9.5
49 movement disease 9.5
50 spinal cord astrocytoma 9.5

Comorbidity relations with Conversion Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Schizophreniform Disorder
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conversion Disorder:



Diseases related to Conversion Disorder

Symptoms & Phenotypes for Conversion Disorder

UMLS symptoms related to Conversion Disorder:


waxy flexibility

MGI Mouse Phenotypes related to Conversion Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.26 ALX3 COMT GAD1 TRAPPC9
2 respiratory system MP:0005388 8.92 ALX3 COMT GAD1 TRAPPC9

Drugs & Therapeutics for Conversion Disorder

Drugs for Conversion Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 124-94-7 31307
3
Sertraline Approved Phase 4 79617-96-2 68617
4
Rasagiline Approved Phase 4 136236-51-6 3052776
5
Verteporfin Approved, Investigational Phase 4,Not Applicable 129497-78-5
6 Antidepressive Agents Phase 4
7 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
8 Neurotransmitter Uptake Inhibitors Phase 4,Not Applicable
9 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Not Applicable
10 Serotonin Agents Phase 4,Not Applicable
11 Serotonin Uptake Inhibitors Phase 4,Not Applicable
12 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 triamcinolone acetonide Phase 4,Phase 3,Not Applicable
15 Triamcinolone diacetate Phase 4,Phase 3,Not Applicable
16 Triamcinolone hexacetonide Phase 4,Phase 3,Not Applicable
17 Monoamine Oxidase Inhibitors Phase 4
18 Neuroprotective Agents Phase 4
19 Protective Agents Phase 4
20 Immunosuppressive Agents Phase 4,Phase 3
21 Dermatologic Agents Phase 4,Not Applicable
22 Photosensitizing Agents Phase 4,Not Applicable
23
Serotonin Investigational, Nutraceutical Phase 4,Not Applicable 50-67-9 5202
24
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
25
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
26
Temazepam Approved, Investigational Phase 3,Phase 2,Not Applicable 846-50-4 5391
27
Dalteparin Approved Phase 3 9005-49-6
28
Fluorouracil Approved Phase 3 51-21-8 3385
29
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
30
Iodine Approved, Investigational Phase 3 7553-56-2 807
31
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
32
Povidone Approved Phase 3 9003-39-8
33
Povidone-iodine Approved Phase 3 25655-41-8
34 Adrenergic Agents Phase 2, Phase 3
35 Adrenergic Antagonists Phase 2, Phase 3
36 Adrenergic beta-Antagonists Phase 2, Phase 3
37 Anti-Arrhythmia Agents Phase 2, Phase 3
38 Antihypertensive Agents Phase 2, Phase 3
39 Vasodilator Agents Phase 2, Phase 3
40 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
41 Tranquilizing Agents Phase 3,Phase 2,Not Applicable
42 Pharmaceutical Solutions Phase 3
43 Anti-Anxiety Agents Phase 3,Phase 2,Not Applicable
44 GABA Agents Phase 3,Phase 2,Not Applicable
45 GABA Modulators Phase 3,Phase 2,Not Applicable
46 Hypnotics and Sedatives Phase 3,Phase 2,Not Applicable
47 Anticoagulants Phase 3
48 Antimetabolites Phase 3
49 Antimetabolites, Antineoplastic Phase 3
50 calcium heparin Phase 3

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
2 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
3 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
4 Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment Completed NCT01722656 Phase 4 Aflibercept
5 Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments Completed NCT00976222 Phase 4 intravitreal injection with ranibizumab
6 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4 Eylea
7 Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Recruiting NCT02068625 Phase 4 Rasagiline;Placebo
8 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
9 Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment Unknown status NCT00404209 Phase 3
10 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
11 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
12 A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol Unknown status NCT01127568 Phase 2, Phase 3 Propranolol is available in generic form as the Wyeth product under the trade name Inderal.
13 Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments Completed NCT00590694 Phase 2, Phase 3 ranibizumab
14 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Recruiting NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
15 Treatment of Globus Sensations With Psychotherapy Active, not recruiting NCT01590992 Phase 2, Phase 3
16 Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy Active, not recruiting NCT01976923 Phase 3 Intravitreal bevacizumab
17 Rehabilitation of Conversion Gait Disorder Unknown status NCT01422278 Phase 1, Phase 2
18 Lucentis to Treat Pigment Epithelial Detachment Completed NCT00841581 Phase 2 Ranibizumab
19 Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations Completed NCT00831350 Phase 2 Ranibizumab
20 Body-Oriented Therapy for Sexual Abuse Recovery Completed NCT00097305 Phase 2
21 Ranibizumab for Diabetic Traction Retinal Detachment Completed NCT01201161 Phase 2 Ranibizumab
22 Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA) Completed NCT00690768 Phase 2 Bevacizumab
23 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
24 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
25 Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment Terminated NCT00083967 Phase 2 denufosol tetrasodium (INS37217) Intravitreal Injection
26 HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration Terminated NCT01189019 Phase 2 ranibizumab;ranibizumab
27 Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Unknown status NCT01261533 Phase 1
28 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Unknown status NCT00548197 Phase 1 Bevacizumab
29 A Study in Subjects With Retinal Detachment Completed NCT00210067 Phase 1 denufosol tetrasodium (INS37217) Intravitreal Injection
30 Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments Completed NCT00749021 Phase 1 Ranibizumab;Ranibizumab;Ranibizumab;Ranibizumab
31 Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment Recruiting NCT02841306 Phase 1 Ursodeoxycholic Acid
32 Psychotherapy and Pharmacotherapy in Dissociative Disorders Unknown status NCT00630981 Pharmacological treatment (Quetiapine and/or Escitalopram)
33 Psychopathology of Dissociative Disorders Unknown status NCT01388140
34 Comparing Different Treatments in Reducing Dissociative Seizure Occurrence Unknown status NCT02325544 Not Applicable
35 Cognitive Behavioural Therapy in Dissociative Seizures Unknown status NCT00688727 Not Applicable
36 Multi-electrocoagulation Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye Unknown status NCT02201706 Not Applicable
37 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Unknown status NCT01959568 Not Applicable
38 DOREFA (Retinal Detachment: Function and Anatomy) Unknown status NCT01767038 Not Applicable
39 Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment Unknown status NCT02185469 Not Applicable sulfur hexafluoride (SF6)
40 Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration Unknown status NCT01521819 Not Applicable Lucentis
41 Cytokine Levels in Conversion Disorder Completed NCT00971360
42 Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder Completed NCT02329626
43 Prevalence of Dissociative Disorders in Children Completed NCT01512641 Not Applicable
44 Brain Activity in People With Functional Movement Disorders Completed NCT00448084
45 Treatment of Functional Movement Disorders With Psychotherapy Completed NCT01778517 Not Applicable
46 TMS and Attentional Bias in Functional Motor Disorder Completed NCT02102906 Not Applicable
47 Feasibility Study of Physiotherapy for Functional Motor Symptoms Completed NCT02275000 Not Applicable
48 Exploration of the Social Cognition in Adolescents With a Dissociative Disorder or Autism Spectrum Completed NCT01805128 Not Applicable
49 Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic Completed NCT02007928 Not Applicable
50 Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus Completed NCT00381771

Search NIH Clinical Center for Conversion Disorder

Cochrane evidence based reviews: conversion disorder

Genetic Tests for Conversion Disorder

Anatomical Context for Conversion Disorder

MalaCards organs/tissues related to Conversion Disorder:

41
Eye, Testes, Brain, Endothelial, Cortex, Prefrontal Cortex, Retina

Publications for Conversion Disorder

Articles related to Conversion Disorder:

(show top 50) (show all 334)
# Title Authors Year
1
Conversion Disorder Diagnosis and Medically Unexplained Symptoms. ( 29697337 )
2018
2
Treatment for Patients With a Functional Neurological Disorder (Conversion Disorder): An Integrated Approach. ( 29606068 )
2018
3
The role of emotion dysregulation in Conversion Disorder. ( 29892968 )
2018
4
Prosopagnosia as a Type of Conversion Disorder. ( 29666739 )
2018
5
A Novel Treatment Protocol (Nocebo Hypothesis Cognitive Behavioural Therapy; NH-CBT) for Functional Neurological Symptom Disorder/Conversion Disorder: A Retrospective Consecutive Case Series. ( 29463338 )
2018
6
Characteristics of Children Hospitalized for Psychogenic Nonepileptic Seizures Due to Conversion Disorder Versus Epilepsy. ( 29739840 )
2018
7
Functional neuroimaging of recovery from motor conversion disorder: A case report. ( 29601954 )
2018
8
Metacognition of visuomotor decisions in conversion disorder. ( 29698734 )
2018
9
Characteristics and Outcomes of Children With Conversion Disorder Admitted to a Single Inpatient Rehabilitation Unit, A Retrospective Study. ( 29550412 )
2018
10
Patients with motor conversion disorder use early developmental motor patterns. ( 29861236 )
2018
11
Systemic Lupus Erythematosus and SjAPgren's Syndrome Complicated by Conversion Disorder: a Case Report. ( 29780064 )
2018
12
Functional neurological symptom disorder (conversion disorder): A role for microglial-based plasticity mechanisms? ( 29406995 )
2018
13
Self-reference, emotion inhibition and somatosensory disturbance: preliminary investigation of network perturbations in conversion disorder. ( 29509290 )
2018
14
When symptoms don't fit: a case series of conversion disorder in the pediatric otolaryngology practice. ( 29843801 )
2018
15
Huntington's Disease in a Patient Misdiagnosed as Conversion Disorder. ( 29670796 )
2018
16
Conversion Disorder. ( 29851882 )
2018
17
Are psychogenic non-epileptic seizures just another symptom of conversion disorder? ( 28235779 )
2017
18
Neuroanatomy of conversion disorder: towards a network approach. ( 29252202 )
2017
19
Conversion Disorder, Functional Neurological Symptom Disorder, and Chronic Pain: Comorbidity, Assessment, and Treatment. ( 28434123 )
2017
20
Downwards Vertical Attention Bias in Conversion Disorder vs Controls: A Pilot Study. ( 28844417 )
2017
21
Symptom-specific amygdala hyperactivity modulates motor control network in conversion disorder. ( 28529870 )
2017
22
Postoperative transient blindness after general anesthesia and surgery: case report of conversion disorder. ( 28936911 )
2017
23
Conversion disorder: A systematic review of current terminology. ( 28274339 )
2017
24
Postoperative Conversion Disorder Presenting as Inspiratory Stridor and Hemiparesis in a Pediatric Patient. ( 28093564 )
2017
25
Stiff person case misdiagnosed as conversion disorder: A case report. ( 29201327 )
2017
26
Psychometric properties of Conversion Disorder Scale- Revised (CDS) for children. ( 28507360 )
2017
27
Conversion disorder or multiple sclerosis? ( 28784382 )
2017
28
Conversion Disorder Comorbidity and Childhood Trauma. ( 28566953 )
2017
29
La belle indiffAcrence revisited: a case report on progressive supranuclear palsy misdiagnosed as conversion disorder. ( 28814874 )
2017
30
A Case of Sporadic Creutzfeldt-Jakob Disease Presenting as Conversion Disorder. ( 28553554 )
2017
31
The classification of conversion disorder (functional neurologic symptom disorder) in ICD and DSM. ( 27719838 )
2017
32
Functional networks of motor inhibition in conversion disorder patients and feigning subjects. ( 27330971 )
2016
33
Conversion Disorder in an Appalachian Community. ( 27490651 )
2016
34
Clinical Considerations Regarding Regression in Psychotherapy with Patients with Conversion Disorder. ( 27603802 )
2016
35
Childhood Trauma and Alexithymia in Patients with Conversion Disorder. ( 27504555 )
2016
36
Can motor imagery and hypnotic susceptibility explain Conversion Disorder with motor symptoms? ( 27346334 )
2016
37
Functional Neuroanatomy and Neurophysiology of Functional Neurological Disorders (Conversion Disorder). ( 26900733 )
2016
38
Poster 173 Concussions Presenting with Conversion Disorder: AA Case Series. ( 27672938 )
2016
39
Evaluation of oxidant, antioxidant, and S100B levels in patients with conversion disorder. ( 27471386 )
2016
40
Aversive stimuli exacerbate defensive motor behaviour in motor conversion disorder. ( 27842291 )
2016
41
Erratum: Uncovering the etiology of conversion disorder: insights from functional neuroimaging [Corrigendum]. ( 27103807 )
2016
42
Demonstration of Injury of the Corticospinal Tract in a Patient with Suspected Motor Conversion Disorder. ( 27386816 )
2016
43
Neural correlates of conversion disorder: overview and meta-analysis of neuroimaging studies on motor conversion disorder. ( 27283002 )
2016
44
Poster 294 Conversion Disorder Rehabilitation: A Case Report. ( 27673051 )
2016
45
Cognitive Behavioural Therapy and Adjunctive Physical Activity for Functional Movement Disorders (Conversion Disorder): A Pilot, Single-Blinded, Randomized Study. ( 27744440 )
2016
46
Postoperative conversion disorder. ( 27041258 )
2016
47
The role of psychiatrists in diagnosing conversion disorder: a mixed-methods analysis. ( 27274253 )
2016
48
Life events and escape in conversion disorder. ( 27377290 )
2016
49
From conversion disorder (DSM-IV-TR) to functional neurological symptom disorder (DSM-5): When a label changes the perspective for the neurologist, the psychiatrist and the patient. ( 26723973 )
2016
50
Uncovering the etiology of conversion disorder: insights from functional neuroimaging. ( 26834476 )
2016

Variations for Conversion Disorder

Expression for Conversion Disorder

Search GEO for disease gene expression data for Conversion Disorder.

Pathways for Conversion Disorder

Pathways related to Conversion Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
9.97 COMT GAD1

GO Terms for Conversion Disorder

Sources for Conversion Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....